CO2022016630A2 - Composiciones farmacéuticas inyectables y usos de las mismas - Google Patents
Composiciones farmacéuticas inyectables y usos de las mismasInfo
- Publication number
- CO2022016630A2 CO2022016630A2 CONC2022/0016630A CO2022016630A CO2022016630A2 CO 2022016630 A2 CO2022016630 A2 CO 2022016630A2 CO 2022016630 A CO2022016630 A CO 2022016630A CO 2022016630 A2 CO2022016630 A2 CO 2022016630A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- injectable pharmaceutical
- moxidectin
- combination
- well
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones inyectables que comprenden la combinación de un compuesto de isoxazolina, así como una lactona macrocíclica fisiológicamente activa como la moxidectina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20175597 | 2020-05-20 | ||
PCT/EP2021/063236 WO2021233967A1 (en) | 2020-05-20 | 2021-05-19 | Injectable pharmaceutical compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022016630A2 true CO2022016630A2 (es) | 2022-11-29 |
Family
ID=70779586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0016630A CO2022016630A2 (es) | 2020-05-20 | 2022-11-18 | Composiciones farmacéuticas inyectables y usos de las mismas |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230310386A1 (es) |
EP (1) | EP4153133B1 (es) |
JP (2) | JP7447315B2 (es) |
CN (1) | CN115666514A (es) |
AU (1) | AU2021277491B2 (es) |
BR (1) | BR112022022923A2 (es) |
CA (1) | CA3182659A1 (es) |
CL (1) | CL2022003194A1 (es) |
CO (1) | CO2022016630A2 (es) |
DK (1) | DK4153133T3 (es) |
ES (1) | ES2969653T3 (es) |
FI (1) | FI4153133T3 (es) |
IL (1) | IL298259A (es) |
MX (1) | MX2022014493A (es) |
PT (1) | PT4153133T (es) |
WO (1) | WO2021233967A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146020B (zh) * | 2022-02-10 | 2022-04-29 | 中国远大集团有限责任公司 | 一种注射美容产品及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916154A (en) | 1986-09-12 | 1990-04-10 | American Cyanamid Company | 23-Imino derivatives of LL-F28249 compounds |
ES2086022T3 (es) | 1991-07-23 | 1996-06-16 | American Cyanamid Co | Composiciones estables para administracion parenteral y su uso. |
ATE392887T1 (de) | 2000-10-10 | 2008-05-15 | Wyeth Corp | Stabilisierte arzneizusammensetzungen zur parenteralen vearbreichung |
JP4883296B2 (ja) | 2004-03-05 | 2012-02-22 | 日産化学工業株式会社 | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 |
US8362086B2 (en) | 2005-08-19 | 2013-01-29 | Merial Limited | Long acting injectable formulations |
TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
PL2957284T3 (pl) | 2007-06-27 | 2018-08-31 | E. I. Du Pont De Nemours And Company | Sposób zwalczania szkodników zwierzęcych |
TWI556741B (zh) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
BRPI0705822A2 (pt) * | 2007-10-25 | 2009-06-23 | Schering Plough Saude Animal Ltda | formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável |
WO2009063910A1 (ja) | 2007-11-12 | 2009-05-22 | Nissan Chemical Industries, Ltd. | 光学活性イソキサゾリン化合物の触媒的不斉合成方法 |
TWI411395B (zh) | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
CA2747060A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
JP5608676B2 (ja) | 2008-12-19 | 2014-10-15 | ノバルティス アーゲー | イソオキサゾリン誘導体及びその殺虫剤としての使用 |
JP5679102B2 (ja) | 2009-08-03 | 2015-03-04 | 日産化学工業株式会社 | ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法 |
TWI487486B (zh) | 2009-12-01 | 2015-06-11 | Syngenta Participations Ag | 以異唑啉衍生物為主之殺蟲化合物 |
WO2011124998A1 (en) | 2010-04-08 | 2011-10-13 | Pfizer Inc. | Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides |
RS59297B1 (sr) | 2012-09-07 | 2019-10-31 | Zoetis Services Llc | Paraziticidalne kombinacije spirocikličnog izoksazolina |
JP6209272B2 (ja) | 2013-09-30 | 2017-10-04 | ゾエティス・サービシーズ・エルエルシー | 長時間作用型スピロイソキサゾリン製剤 |
UY36570A (es) | 2015-02-26 | 2016-10-31 | Merial Inc | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas |
SG10201912724SA (en) * | 2015-04-08 | 2020-02-27 | Boehringer Ingelheim Animal Health Usa Inc | Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
UY37137A (es) | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
WO2019012377A1 (en) | 2017-07-10 | 2019-01-17 | Basf Se | MIXTURES COMPRISING AN INSECTICIDE AND A NITRIFICATION INHIBITOR SUCH AS 2- (3,4-DIMETHYL-1H-PYRAZOL-1-YL) SUCCINIC ACID (DMPSA) OR 3,4-DIMETHYL PYRAZOLIUM GLYCOLATE (DMPG) |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
PE20201150A1 (es) * | 2017-11-07 | 2020-10-26 | Intervet Int Bv | Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas |
CN111295375A (zh) | 2017-11-07 | 2020-06-16 | 英特维特国际股份有限公司 | 制备大尺寸异噁唑啉粒子的方法 |
-
2021
- 2021-05-19 PT PT217278217T patent/PT4153133T/pt unknown
- 2021-05-19 JP JP2022570365A patent/JP7447315B2/ja active Active
- 2021-05-19 MX MX2022014493A patent/MX2022014493A/es unknown
- 2021-05-19 IL IL298259A patent/IL298259A/en unknown
- 2021-05-19 AU AU2021277491A patent/AU2021277491B2/en active Active
- 2021-05-19 EP EP21727821.7A patent/EP4153133B1/en active Active
- 2021-05-19 CN CN202180036476.9A patent/CN115666514A/zh active Pending
- 2021-05-19 DK DK21727821.7T patent/DK4153133T3/da active
- 2021-05-19 WO PCT/EP2021/063236 patent/WO2021233967A1/en active Application Filing
- 2021-05-19 ES ES21727821T patent/ES2969653T3/es active Active
- 2021-05-19 BR BR112022022923A patent/BR112022022923A2/pt unknown
- 2021-05-19 US US17/999,024 patent/US20230310386A1/en active Pending
- 2021-05-19 FI FIEP21727821.7T patent/FI4153133T3/fi active
- 2021-05-19 CA CA3182659A patent/CA3182659A1/en active Pending
-
2022
- 2022-11-16 CL CL2022003194A patent/CL2022003194A1/es unknown
- 2022-11-18 CO CONC2022/0016630A patent/CO2022016630A2/es unknown
-
2023
- 2023-10-23 JP JP2023181876A patent/JP2024010068A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023523476A (ja) | 2023-06-05 |
JP2024010068A (ja) | 2024-01-23 |
ES2969653T3 (es) | 2024-05-21 |
AU2021277491B2 (en) | 2024-05-16 |
CL2022003194A1 (es) | 2023-02-03 |
WO2021233967A1 (en) | 2021-11-25 |
MX2022014493A (es) | 2022-12-13 |
IL298259A (en) | 2023-01-01 |
CN115666514A (zh) | 2023-01-31 |
DK4153133T3 (da) | 2024-02-05 |
EP4153133A1 (en) | 2023-03-29 |
AU2021277491A1 (en) | 2022-12-01 |
PT4153133T (pt) | 2024-01-12 |
BR112022022923A2 (pt) | 2022-12-20 |
CA3182659A1 (en) | 2021-11-25 |
FI4153133T3 (fi) | 2024-01-30 |
EP4153133B1 (en) | 2023-11-08 |
JP7447315B2 (ja) | 2024-03-11 |
US20230310386A1 (en) | 2023-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
CL2022000250A1 (es) | Molécula de unión al antígeno multiespecífica que tiene actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii) y formulación farmacéutica que contiene tal molécula como ingrediente activo (divisional de la solicitud n°202000767) | |
DOP2020000023A (es) | Nuevos derivados de quinolina | |
CY1114575T1 (el) | Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του | |
CO2019014484A2 (es) | Nuevos derivados de azaquinolina | |
CO2021005226A2 (es) | Nuevos compuestos antihelmínticos | |
CO2022016630A2 (es) | Composiciones farmacéuticas inyectables y usos de las mismas | |
CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
UY37981A (es) | Novedosos antagonistas del receptor b2 de bradiquinina | |
UY37832A (es) | Dihidrooxadiazinonas | |
CO2020013876A2 (es) | Nuevos derivados de quinolina | |
CO2021012559A2 (es) | Compuestos macrocíclicos como agonistas de sting | |
CR20110190A (es) | Agente rodenticida sinérgico | |
PE20220510A1 (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana | |
CO2022002898A2 (es) | Composiciones que comprenden tigolaner para el control de parásitos | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
BR112023000463A2 (pt) | Macrociclos e seu uso | |
BR112023002631A2 (pt) | Composição atraente de bactrocera oleae e suas utilizações | |
CL2021002373A1 (es) | Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármaco | |
PE20221272A1 (es) | Agente supresor del sabor desagradable | |
CO2023000858A2 (es) | Inhibidores de atr y usos de estos | |
AR126383A1 (es) | Combinaciones insecticidas que comprenden un compuesto de antranilamida y tau-fluvalinato | |
CL2022002786A1 (es) | Formas cristalinas de compuestos orgánicos | |
CO2021008962A2 (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos | |
UY39094A (es) | Composición farmacéutica que comprende compuesto derivado de bencimidazol |